Patients who have undergone coronary artery bypass graft (CABG) surgery for acute coronary syndrome (ACS) derive particular benefit from the addition of ezetimibe to statin therapy. This finding comes from an analysis of the IMPROVE-IT trial in which 18,134 patients with ACS were randomly allocated to simvastatin plus either ezetimibe or placebo. Patients who had previously undergone CABG surgery (9.3% of the participants) and who received simvastatin and ezetimibe had an 8.8% lower absolute risk of the primary end point (cardiovascular death, major coronary event, or stroke) compared with those who received simvastatin and placebo. By contrast, patients who had no history of CABG surgery had a 1.3% lower absolute risk with ezetimibe compared with placebo. “The benefit of adding ezetimibe to statin appears to be enhanced in patients with prior CABG [surgery],” summarize the investigators, but emphasize that patients without previous CABG surgery should not necessarily be excluded from intensive lipid-lowering therapy after ACS.